sorafenib
information and resources from the National Cancer Institute
sorafenib
A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.
|
|
|
|
news articles
Bayer cancer drug gets Swiss approval 01 Apr 2006
Pharmaceutical Business Review Nexavar (sorafenib) tablets will be indicated for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer, after nepherectomy and ...
Onyx Pharmaceuticals to Present at Future Leaders in the Biotech ... Mar 24, 2006
Yahoo! News (press release) With its collaborators, the company is developing small molecule drugs, including Nexavar® (sorafenib) tablets with Bayer Pharmaceuticals Corporation. ...
Merck stands aside as Bayer scoops up Schering Mar 27, 2006
Pharma Times (subscription), Meanwhile, Bayer has potential blockbusters on its hands with Nexavar (sorafenib) for kidney cancer and the oral Factor Xa inhibitor, in trials for deep vein ...
Updated Guidelines for Treatment of Advanced Kidney Cancer Mar 27, 2006
Cancer Consultants (press release), They are Sutent® (sunitinib) and Nexavar® (sorafenib); both drugs target enzymes involved in tumor growth and tumor blood supply. ...
No Advantage With Thalidomide For Metastatic Renal Cell Carcinoma Mar 17, 2006
UroToday, They note that other antiangiogenic drugs, such as bevacizumab, sorafenib and sunitinib, "may have more promising activity in metastatic RCC.".
Bayer rides forth as Schering's white knight Mar 24, 2006
Pharma Times (subscription), It has potential blockbusters on its hands with Nexavar (sorafenib) for kidney cancer and the antithrombotic Factor Xa inhibitor. ...
Therapy for metastatic renal cell carcinoma remains inadequate Mar 9, 2006
News-Medical.net, The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the ...
NCCN Announces Important Updates to Kidney Cancer Clinical ... Mar 7, 2006
Genetic Engineering News, Two kinase inhibitors, sorafenib (Nexavar, Bayer) and sunitinib (Sutent, Pfizer) were recently approved by the FDA and incorporated into the first and second ...
Bayer's share price falls on 4Q results Mar 6, 2006
Pharma Times (subscription), He reiterated the view that two of Bayer's new drugs, Nexavar (sorafenib) for non-small cell lung cancer and the oral Factor Xa inhibitor for thrombotic ...
Mixed feeling over Bayer results Mar 7, 2006
Pharma Times (subscription), HealthCare segment looks set to continue turning in solid results and positive news flow for the foreseeable future, especially if Nexavar (sorafenib) does as ...
German Stocks Rise for Fourth Day in Five, Led by Linde, Bayer 21 Dec 2005
Bloomberg Bayer AG, Germany's biggest health-care company, rose 57 cents, or 1.7 percent, to 35.02 euros after the sorafenib drug it developed with Onyx Pharmaceuticals ...
NEWS RELEASE 21 Dec 2005
Financial News USA (press release), ...(Nasdaq: ONXX) recently announced that the US Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) tablets for the treatment of patients with ...
Study latest to link men's impotence, heart disease 21 Dec 2005
Charlotte Observer, It's the first new treatment option for kidney cancer patients in more than a decade.Nexavar, also known as sorafenib tosylate, is for patients with advanced ...
Sorafenib Shows Benefits in Combination with Gemcitabine in ... Nov 22, 2005
DG News PHILADELPHIA, PA -- November 22, 2005 -- A phase 2 study is evaluating the efficacy and toxicity associated with the use of sorafenib plus gemcitabine in ...
Onyx Pharmaceuticals Announces Teleconference and Webcast to ... Dec 20, 2005
PR Newswire (press release), ...(Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss the approval of Nexavar(R) (sorafenib) tablets. ...
Bayer still sees approval for kidney cancer drug Nexavar in US ... Dec 9, 2005
Forbes In addition to kidney cancer, Nexavar - also known as Sorafenib - is being tested in combination with chemotherapy in a Phase III trial for skin cancer, as ...
GlaxoSmithKline cancer drug threatens Herceptin market Dec 9, 2005
Nature.com (subscription), Several multitargeted therapies follow close behind in phase 2 trials: Pfizer's Sutent (sunitinib malate), Bayer's Nexavar (sorafenib) and AstraZeneca's ZD6474 ...
Bayer hikes peak sales potential for drugs Nexavar, Kogenate ... Dec 7, 2005
Forbes Nexavar, also known as Sorafenib, is a collaboration with US-based Onyx Pharmaceuticals and is currently expected to be launched on the US and European markets ...
Bayer hikes peak sales potential for drugs Nexavar, Kogenate ... Dec 8, 2005
Forbes Nexavar, also known as Sorafenib, is developed in a collaboration with US-based Onyx Pharmaceuticals and is currently expected to be launched on the US and ...
(Euronext Paris) - Bayer : "We have great confidence for the ... Dec 8, 2005
Euronext, ...ingredient: sorafenib) is scheduled to begin in the first half of 2006 for the additional indication of lung cancer. "This raises the product’s sales. ...
Investor conference in London on research and development Dec 8, 2005
Biotech Intelligence (press release), ...this business," the Bayer CEO said, adding that Phase III clinical testing of the new cancer drug Nexavar® (active ingredient: sorafenib) is scheduled to ...
Cancer Treatment Market for Vascular Endothelial Growth Factor ... Nov 29, 2005
PR Newswire (press release), ..."These therapies include Bayer/Onyx Pharmaceuticals' sorafenib and Pfizer's sutent (sunitinib) for chemotherapy refractory renal cell carcinoma; Novartis ...
The Market for Existing Targeted Therapies Worth $5.1 Billion in ... Nov 23, 2005
Genetic Engineering News, Those products developed to inhibit multiple pathways show the most promise, particularly Onyx Pharmaceuticals/Bayers' sorafenib and Bristol-Myers Squibb's ...
Onyx Prices $126M Offering To Pay For Growing Nexavar Costs Nov 18, 2005
BioWorld Online (subscription), By Aaron Lorenzo. To offset rising expenses related to its lead product, Nexavar (sorafenib tosylate), Onyx Pharmaceuticals Inc. ...
Onyx Announces Pricing of Public Offering Nov 18, 2005
Yahoo! News (press release) ...onyx-pharm.com. Nexavar® (sorafenib tosylate) Tablets is a registered trademark of Bayer Pharmaceuticals Corporation. This news ...
Onyx Announces Pricing of Public Offering Nov 18, 2005
PR Newswire (press release), ...pharm.com. Nexavar(R) (sorafenib tosylate) Tablets is a registered trademark of Bayer Pharmaceuticals Corporation. Forward Looking ...
|
|
